3 ms·
I’m not sure your example of increased risk of suicide is a good one - the FDA already responded to that data and increases warnings. Sounds like the system wo
by refurb 7y ago
I’m not sure your example of increased risk of suicide is a good one - the FDA already responded to that data and increases warnings. Sounds like the system worked.
This is a pretty good paper that covers the issue. It wasn't that straightforward to actually get reliable data and the author here is arguing that the pendulum swung too far - adolescents weren't get antidepressants because doctors were so scared of the boxed warning the FDA added.[1]
And there is likely a bit of 20/20 hindsight going on here. Clinical trial is never black and white. You can get “signals” in the data that aren’t real, especially if the trial wasn’t powered well enough.
If we pulled drugs from the market every time someone found a signal, we’d probably have 10% of the drugs we do now, and people would be denied any benefit.
Drug development is all about risk versus benefit, and yes, the FDA is willing to approve a drug with significant risks if the drug is treating a serious disease.
[1]https://www.psychiatrictimes.com/special-reports/relationship-between-antidepressant-initiation-and-suicide-risk https://www.psychiatrictimes.com/special-reports/relationshi...